Last 500.05 INR
Change Today +13.40 / 2.75%
Volume 1.3M
BIOS On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

biocon ltd (BIOS) Snapshot

Open
489.25
Previous Close
486.65
Day High
501.75
Day Low
485.00
52 Week High
07/4/14 - 553.70
52 Week Low
10/21/13 - 323.45
Market Cap
100.0B
Average Volume 10 Days
1.6M
EPS TTM
21.08
Shares Outstanding
200.0M
EX-Date
07/10/14
P/E TM
23.7x
Dividend
5.00
Dividend Yield
1.00%
Current Stock Chart for BIOCON LTD (BIOS)

Related News

No related news articles were found.

biocon ltd (BIOS) Related Businessweek News

No Related Businessweek News Found

biocon ltd (BIOS) Details

Biocon Limited develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, opthalmics, peptides, oral anti-diabetic agents, anti-inflammatory agents, hepatoprotective agents, and probiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of diabetology, oncotherapeutic, nephrology, cardiology, immunotherapy, comprehensive care and bioproducts; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company was founded in 1978 and is headquartered in Bengaluru, India.

7,310 Employees
Last Reported Date: 06/26/14
Founded in 1978

biocon ltd (BIOS) Top Compensated Officers

Founder, Chairman, Managing Director, Member ...
Total Annual Compensation: 14.1M
Compensation as of Fiscal Year 2014.

biocon ltd (BIOS) Key Developments

Biocon Limited Approves Dividend, Payable on July 31, 2014

Biocon Limited announced that the dividend of INR 5 per equity share approved by the members of the company at the annual general meeting held on July 25, 2014 will be paid out on July 31, 2014.

Biocon Limited Announces Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2014

Biocon Limited announced unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2014. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) was INR 7,188.1 million compared to INR 6,947.6 million for the same period a year ago. Profit from operations before other income and finance cost was INR 1,220.1 million compared to INR 1,037.9 million for the same period a year ago. Profit from ordinary activities after finance cost and before tax was INR 1,386.4 million compared to INR 1,262.7 million for the same period a year ago. Net profit after tax and minority interest was INR 1,029.1 million or INR 5.20 per diluted share compared to net profit of INR 935.0 million or INR 4.73 per diluted share for the same period a year ago. EBITDA was INR 1,910 million compared to INR 1,750 million for the same period a year ago. The company posted a 9% year-on-year increase in net profit for the quarter, helped by licensing income and a better product mix, though revenues were muted. Total revenue grew 3% to INR 7,420 million, with its core biopharma business showing a marginal decline, which was largely because of the impact from geopolitical turmoil in the Middle East and North Africa region. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) was INR 5,346.0 million compared to INR 5,228.9 million for the same period a year ago. Profit from operations before other income and finance cost was INR 856.6 million compared to INR 855.9 million for the same period a year ago. Profit from ordinary activities after finance cost and before tax was INR 971.3 million compared to INR 1,122.3 million for the same period a year ago. Net profit was INR 746.3 million or INR 3.77 per diluted share compared to net profit of INR 877.3 million or INR 4.44 per diluted share for the same period a year ago.

Biocon Limited Appoints Siddharth Mittal as Chief Financial Officer, Effective August 01, 2014

Biocon Limited announced the appointment of Mr. Siddharth Mittal, President-Finance as chief financial officer, effective August 01, 2014. He joined the company in May 2013 and takes over from Mr. Murali Krishnan, who retires after more than 30 years of distinguished service with the organization.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOS:IN 500.05 INR +13.40

BIOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $17.35 USD +0.09
Cambrex Corp $22.29 USD +0.12
Depomed Inc $14.96 USD -0.07
Divi's Laboratories Ltd 1,740 INR +47.20
Piramal Enterprises Ltd 789.25 INR +3.15
View Industry Companies
 

Industry Analysis

BIOS

Industry Average

Valuation BIOS Industry Range
Price/Earnings 22.5x
Price/Sales 3.2x
Price/Book 3.0x
Price/Cash Flow 15.2x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCON LTD, please visit www.biocon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.